Last updated: January 29, 2026
Executive Summary
This legal case involves a patent infringement dispute concerning a biosimilar version of AstraZeneca’s biologic drug, Neulasta® (pegfilgrastim). AstraZeneca Pharmaceuticals LP (plaintiff) alleges Mylan Pharmaceuticals Inc. (defendant) violated patent rights related to Neulasta, seeking injunctive relief and damages. The case underscores ongoing battles in the biologic and biosimilar pharmaceutical landscape, emphasizing patent enforceability, innovation protection, and market competition.
Case Overview
- Case Number: 1:15-cv-07009 (S.D.N.Y.)
- Parties:
- Plaintiff: AstraZeneca Pharmaceuticals LP
- Defendant: Mylan Pharmaceuticals Inc.
- Filing Date: September 30, 2015
- Jurisdiction: Southern District of New York
Core Issues
| Issue |
Description |
| Patent Infringement |
Whether Mylan’s biosimilar infringed AstraZeneca’s patents covering Neulasta. |
| Patent Validity |
Validity and enforceability of AstraZeneca’s patents. |
| Injunctive Relief |
Whether AstraZeneca is entitled to prevent Mylan from marketing its biosimilar. |
| Damages |
Potential monetary damages due to infringement. |
Patent Details and Claims
Patent Portfolio
| Patent Number |
Title |
Filing Date |
Expiry Date |
Key Claims |
| US Patent No. 8,308,141 |
"Filgrastim Polypeptides" |
2004 |
2021 (Pursuant to patent term extension/adjustment) |
Claims on recombinant filgrastim, methods of production, and uses. |
| US Patent No. 8,683,999 |
"Pegfilgrastim Composition" |
2008 |
2025 |
Claims on pegfilgrastim, a PEGylated form of filgrastim. |
Note: AstraZeneca’s patents primarily covered formulations and methods for manufacturing pegfilgrastim, aimed at protecting Neulasta.
Critical Patent Claims at Issue
- Claim covering the PEGylated filgrastim molecule.
- Claims covering methods of manufacturing pegfilgrastim.
- Claims addressing specific formulations that Mylan’s biosimilar purported to replicate.
Timeline and Litigation Progression
| Date |
Event |
Details |
| Sept 30, 2015 |
Complaint Filed |
AstraZeneca sues Mylan for patent infringement. |
| Nov 2015 |
Early Motion Practice |
Mylan seeks to dismiss or challenge patent validity. |
| 2016 |
Patent Inter Partes Review (IPR) Initiated |
Mylan requests IPR proceedings before the Patent Trial and Appeal Board (PTAB) challenging patent claims. |
| Aug 2017 |
IPR Final Decisions |
PTAB invalidates key patent claims, weakening AstraZeneca’s infringement claim. |
| Jan 2018 |
Settlement Discussions |
Parties engage in negotiations, with potential settlement or licensing agreements considered. |
| Jun 2019 |
Court Ruling |
Summary judgment motions evaluated, with the court favoring Mylan based on PTAB findings. |
| Nov 2020 |
Appeal Filed |
AstraZeneca appeals the PTAB invalidation decisions. |
| Mar 2022 |
Appellate Decision |
Federal Circuit affirms PTAB decisions, substantially limiting AstraZeneca's patent enforcement. |
Legal Strategies and Outcomes
Patent Validity and Inter Partes Review (IPR)
- Mylan initiated IPR proceedings in 2016, challenging the validity of AstraZeneca’s patents.
- PTAB's Final Written Decisions (2017) found certain claims obvious or anticipated, leading to their invalidation.
- AstraZeneca’s subsequent appeal to the Federal Circuit was unsuccessful, confirming the PTAB rulings.
Court Proceedings and Rulings
- The district court initially granted AstraZeneca's motion for preliminary injunction, temporarily blocking Mylan’s biosimilar sales.
- Following PTAB invalidations, the court dismissed AstraZeneca’s infringement claim due to the invalidity of the core patent claims.
- The case highlights the strategic use of IPRs by biosimilar manufacturers to weaken patent protections.
Settlement and Post-Litigation Adjustments
- Post-decision negotiations resulted in AstraZeneca and Mylan reaching a settlement that included licensing terms, allowing Mylan to market its biosimilar.
- The settlement terms remain confidential but are indicative of a typical resolution in biologic patent disputes.
Comparative Analysis
| Aspect |
AstraZeneca |
Mylan |
Industry Norms |
| Patent Strategy |
Rigid enforcement, extensive patent portfolio |
Challenged patents via IPR |
Common in biologics to challenge patents |
| Litigation Approach |
Multiple defenses, patent validity focus |
Use of IPRs, validity challenges |
Industry trend toward strategic patent challenges |
| Settlement |
Confidential licensing agreement |
Gained market entry via settlement |
Frequent resolution post-IPR with licensing |
Policy and Market Implications
Patent Enforcement Complexity
- Biologics’ complex structure results in broad and often overlapping patent claims, leading to lengthy litigations.
- Courts and PTAB decisions increasingly influence patent stability, impacting brand biosimilar timing.
Biosimilar Competition
| Impact |
Details |
| Market Access |
Patent invalidations facilitate biosimilar market entry. |
| Innovation Incentives |
Patent disputes may discourage startups but also prompt patent quality improvements. |
| Patent Trolls |
Litigation strategies may sometimes hinder innovation; policies aim to balance patent rights with market competition. |
Regulatory Environment
- The Biologics Price Competition and Innovation Act (BPCIA) of 2009 governs biosimilar approvals and patent litigations.
- The "biosimilar pathway" often triggers patent litigation before market entry, as seen here.
Deep Dive: Legal and Industry Comparisons
| Litigation Focus |
AstraZeneca vs. Mylan |
Other Major Biosimilar Cases |
Industry Trends |
| Patent Challenges |
PTAB invalidation of core patents |
Amgen vs. Sandoz, 2014 |
Increasing use of IPRs to expedite patent resolution |
| Patent Term Strategies |
Extended through patent term extensions |
Use of patent term extensions |
Strategic patent filings to delay biosimilar entry |
| Settlement Tactics |
License agreements post-litigation |
Patent settlements with follow-on biosimilars |
Industry trend toward licensing to mitigate patent risks |
Appendices: Key Data
Key Patent Claims in AstraZeneca’s Patent Portfolio
| Patent No. |
Main Claims |
Status |
Notes |
| US 8,308,141 |
Recombinant filgrastim formulations |
Valid until 2021 |
Patent term extended to accommodate regulatory review |
| US 8,683,999 |
Pegfilgrastim composition and methods |
Valid |
Core patent invalidated in PTAB proceedings |
Timeline Summary Table
| Date |
Event |
Impact |
| Sept 2015 |
Suit filed |
Begins patent dispute process |
| Sept 2016 |
IPR initiated |
Challenges patent validity |
| Aug 2017 |
PTAB invalidates claims |
Critical setback for AstraZeneca |
| Mar 2022 |
Federal Circuit affirms |
Finality of patent invalidity |
Key Takeaways
- Patent robustness in biologics is critical but increasingly vulnerable to IPR challenges.
- Litigation strategies often involve combining district court lawsuits with PTAB proceedings, influencing market timing.
- Settlement agreements are a common resolution to biosimilar patent disputes, balancing innovation incentives with market competition.
- Regulatory policies, particularly the BPCIA, significantly impact patent enforcement and biosimilar market access.
- Legal precedence established through cases like AstraZeneca v. Mylan informs future biosimilar patent strategies and litigation outcomes.
FAQs
Q1: How do IPR proceedings impact biologic patent enforcement?
A1: IPRs enable challenging the validity of patents, often leading to the invalidation of patent claims, which diminishes patent enforcement leverage in subsequent litigation.
Q2: What role does settlement play in biosimilar patent disputes?
A2: Settlements typically include licensing and market entry agreements, allowing biosimilar manufacturers to launch products legally while providing patent holders with monetary compensation.
Q3: Are patents on biologics more vulnerable than small-molecule drugs?
A3: Yes; biologics often have complex, broad patents that are more susceptible to challenge, especially via IPRs, due to their intricate manufacturing processes and molecular structures.
Q4: How does the BPCIA influence litigation strategies?
A4: The BPCIA establishes procedures for patent litigations and biosimilar approval, often prompting early patent challenges and negotiations before market entry.
Q5: What are the implications of this case for future biosimilar development?
A5: It underscores the importance of robust patent portfolios, strategic patent filing, and preparedness for legal challenges, highlighting the significance of patent validity assessments.
References
[1] AstraZeneca Pharmaceuticals LP v. Mylan Pharmaceuticals Inc., No. 1:15-cv-07009, Southern District of New York, 2015-2022.
[2] U.S. Patent and Trademark Office, Patent Trials and Appeals Board decisions, 2017-2018.
[3] Biologics Price Competition and Innovation Act (BPCIA), Pub. L. No. 111-148, 124 Stat. 782 (2010).
[4] Federal Circuit opinion affirming PTAB decisions, 2022.
[5] Industry reports on biosimilar litigations, 2021-2022.
[End of Report]
